Quick Takeaways
- Contrarius Investment Management Ltd filed SCHEDULE 13G/A for INTELLIA THERAPEUTICS, INC COMMON STOCK (NTLA).
- Disclosed ownership: 0.6%.
- Date of event: 31 Dec 2025.
Contrarius Investment Management Ltd - 31 Dec 2025 SCHEDULE 13G/A Report for INTELLIA THERAPEUTICS, INC COMMON STOCK (NTLA)
- Filing Manager
- Contrarius Investment Management Ltd
- Reporting Manager
- Contrarius Investment Management Ltd
- Symbol
- NTLA
- Shares outstanding
- 119,080,000 shares
- Disclosed Ownership
- 714,480 shares
- Ownership
- 0.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 11 Feb 2026, 13:18:54 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 12 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Contrarius Investment Management Ltd disclosed 0.6% ownership in INTELLIA THERAPEUTICS, INC COMMON STOCK (NTLA) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 12 Nov 2025.
- Current filing was accepted on 11 Feb 2026, 13:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Contrarius Investment Management Ltd | 0.6% | 714,480 | 0 | 714,480 | /s/ Thomas Daniel Perkins | Thomas Daniel Perkins / Director | |
| Contrarius Investment Management (Bermuda) Ltd | 0.6% | 714,480 | 0 | 714,480 | /s/ Matt De Kock | Matt De Kock / Director |